WHO定义IDH野生型胶质母细胞瘤放疗后生存的临床、分子与免疫决定因素:大型真实世界队列研究
该研究回顾性纳入832例WHO 2021定义IDH野生型胶质母细胞瘤成人患者,均接受最大安全切除及辅助放疗±化疗。多变量分析显示严重放射性淋巴细胞减少(sRIL)为独立不良预后因素(HR 1.37, 95%CI 1.16–1.63),MGMT甲基化预测替莫唑胺获益,符合Stupp标准者生存更优。
要点
- sRIL(放疗后4个月内CTCAE≥3级淋巴细胞减少)是独立不良预后因素。
- MGMT甲基化预示同步替莫唑胺获益(交互作用P<0.001)。
- 符合Stupp试验入组标准者各MGMT亚组总生存均更优。
核心结论
- 在大型真实世界队列中,sRIL仍是IDH野生型胶质母细胞瘤独立强预后因素。
- MGMT甲基化预测替莫唑胺获益,符合试验入组标准者预后更佳。
- 结果支持对保留淋巴细胞的治疗策略开展前瞻性评估。
研究设计与样本
- 回顾性真实世界队列研究,纳入2014至2024年间832例成人IDH野生型胶质母细胞瘤患者。
- 入组条件为WHO 2021 grade 4 IDH野生型弥漫性胶质瘤,接受最大安全切除及辅助放疗±化疗。
- 另定义符合Stupp标准的试验合格亚组,分析临床、分子及血液学变量。
主要发现
- 中位总生存期为13.0个月。
- 多变量分析中sRIL为更差OS的独立预测因素(HR 1.37, 95%CI 1.16–1.63),已校正MGMT状态、年龄、切除范围及治疗因素。
- MGMT甲基化预测同步替莫唑胺获益(交互作用P<0.001),试验合格患者在各MGMT亚组OS均更长。
- 年龄与放疗后淋巴细胞最低值同生存呈非线性关联。
- 质子治疗与有利但未达统计学显著的OS估计相关(HR 0.87, P=0.11),在试验合格队列中未见获益。
关键数值与推荐
- sRIL定义为放疗后4个月内CTCAE grade ≥ 3级淋巴细胞减少。
- 多变量Cox模型采用LASSO进行变量选择,并采用样条回归处理非线性。
临床怎么用
- 可将放疗后4个月内CTCAE≥3级淋巴细胞减少作为IDH野生型胶质母细胞瘤不良预后标志。
- MGMT甲基化状态可用于预测同步替莫唑胺的生存获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Glioblastoma (WHO grade 4), defined by IDH-wildtype status and associated molecular features, carries poor prognosis, and real-world survival models incorporating molecular and immunologic variables remain limited. Severe radiation-induced lymphopenia (sRIL) is a proposed prognostic factor, but its independent effect in molecularly defined glioblastoma has not been established in the modern era. METHODS: We retrospectively identified 832 adults with glioblastoma, defined as WHO 2021 grade 4 IDH-wildtype diffuse glioma treated with maximal safe resection and adjuvant radiotherapy (RT) with or without chemotherapy between 2014 and 2024. A trial-eligible subgroup was defined using Stupp criteria. Clinical, molecular, and hematologic variables were analyzed. sRIL was defined as CTCAE grade ≥ 3 lymphopenia within 4 months of RT. Multivariable Cox models incorporated LASSO for variable selection and spline regression for non-linearity. RESULTS: Median overall survival (OS) was 13.0 months. On multivariable analysis, sRIL (HR 1.37, 95% CI 1.16–1.63) remained an independent predictor of worse OS after adjustment for MGMT status, age, resection extent, and treatment factors. MGMT methylation predicted benefit from concurrent TMZ (pinteraction<0.001), and trial-eligible patients had longer OS across MGMT subgroups. Age and post-RT lymphocyte nadir were non-linearly associated with survival. Proton therapy was associated with a favorable but non-significant OS estimate (HR 0.87, p = 0.11), with no benefit in the trial-eligible cohort. CONCLUSIONS: In this large, real-world cohort, sRIL remained a strong independent prognostic factor. MGMT methylation predicted TMZ benefit, and trial eligibility conferred favorable outcomes. These findings underscore the prognostic relevance of post-treatment lymphopenia and support prospective evaluation of lymphocyte-sparing treatment strategies.
引用
- Friedes C, Berger M, Linkowski L, et al. Clinical, molecular, and immunologic determinants of survival in WHO-defined IDH-wildtype glioblastoma treated with radiotherapy: a large real-world cohort study. J Neurooncol. 2026. PMID: 42033515. doi:10.1007/s11060-026-05572-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。